The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.

Matthew P.  Goetz

Consulting or Advisory Role - ARC Therapeutics (Inst); AstraZeneca (Inst); BioTheryX; Blueprint Medicines (Inst); Engage Health Media (Inst); Genzyme (Inst); Laekna Therapeutics; Lilly (Inst); Novartis (Inst); Rna Diagnostics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Tersera

Research Funding - AstraZeneca (Inst); Atossa Genetics (Inst); Lilly (Inst); Loxo (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)

Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER

Travel, Accommodations, Expenses - Lilly (Inst)

Seth Andrew  Wander

Consulting or Advisory Role - AstraZeneca; Biovica; Foundation Medicine; Hologic; Lilly; Novartis; Pfizer; Puma Biotechnology; Veracyte

Speakers' Bureau - 2nd.MD; Guardant Health; Lilly; Novartis

Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics; Sermonix Pharmaceuticals

Thomas  Bachelot

Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Seagen

Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Pfizer (Inst); SeaGen (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Novartis; pfizer; Roche

Gerald  Batist

No Relationships to Disclose

Javier  Cortes

Stock and Other Ownership Interests  - Leuko (I); MAJ3 Capital

Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics

Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks

Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)

Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics

Massimo  Cristofanilli

Honoraria - Pfizer

Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Celcuity; Lilly; Menarini; Olaris; Sermonix Pharmaceuticals; Syantra

Research Funding - Angle; AstraZeneca; Lilly; Menarini Silicon Biosystems; Merck

Giuseppe  Curigliano

Leadership - ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=

Honoraria - Ellipses Pharma

Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte

Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen

Research Funding - Merck (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech

Alexandre  de Nonneville

Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Exact Sciences; Gilead Sciences; Lilly; Seagen

Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Menarini; MSD Oncology; Novartis; Pfizer

Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences

Einav Nili  Gal-Yam

Honoraria - AstraZeneca; Lilly; msd; Pfizer; Roche

Consulting or Advisory Role - AstraZeneca; Lilly; MSD Oncology

Travel, Accommodations, Expenses - Gilead Sciences (Inst); Pfizer (Inst)

Komal L.  Jhaveri

Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology

Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical

Cynthia X.  Ma

Consulting or Advisory Role - AstraZeneca; Biovica; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Genzyme; Gilead Sciences; Lilly; Novartis; Olaris; Pfizer; Regor Therapeutics Group; Stemline Therapeutics; Tempus; Tersera; Tersera

Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)

Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.

Travel, Accommodations, Expenses - SABCS; Total Health Conferencing

Heather Anne  Parsons

Honoraria - Guardant Health

Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo/UCB Japan; Natera; SAGA Diagnostics; Sermonix Pharmaceuticals

Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Seagen (Inst)

(OPTIONAL) Uncompensated Relationships - NeoGenomics Laboratories; SAGA Diagnostics

Hope S.  Rugo

Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)

Sarah L  Sammons

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals

Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)

Daniel G.  Stover

Consulting or Advisory Role - Guardant Health

Research Funding - Foundation Medicine (Inst); NeoGenomics Laboratories (Inst)

Patents, Royalties, Other Intellectual Property - Intellectual Property Related to Cancer Diagnostics

Chris  Twelves

Honoraria - Daiichi Sankyo; Eisai; MSD; Novartis; Pfizer

Consulting or Advisory Role - Daiichi Sankyo; Eisai; Pfizer

Speakers' Bureau - Daiichi Sankyo; Eisai; MSD; Pfizer

Research Funding - AstraZeneca; Avacta Life Sciences; Pfizer

Travel, Accommodations, Expenses - Eisai; Gilead Sciences; MSD Oncology; Pfizer

Aditya  Bardia

Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi

Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)

Paul V  Plourde

Employment - Sermonix Pharmaceuticals

Stock and Other Ownership Interests  - Sermonix Pharmaceuticals

David Jay  Portman

Employment - Sermonix Pharmaceuticals

Leadership - Sermonix Pharmaceuticals

Stock and Other Ownership Interests  - Sermonix Pharmaceuticals

Other Relationship - Sermonix Pharmaceuticals (I)

Senthil  Damodaran

Consulting or Advisory Role - AstraZeneca; Taiho Oncology

Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); DualityBio (Inst); EMD Serono (Inst); Guardant Health (Inst); MediLink Therapeutics (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)